RecruitingNCT06169033
Radiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)
Sponsor
China-Japan Friendship Hospital
Enrollment
800 participants
Start Date
Jan 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Using radiomics of intra-abdominal and subcutaneous adipose tissue and clinical features to predict the weight loss efficacy and remission of type 2 diabetes mellitus after bariatric surgery.
Eligibility
Min Age: 16 YearsMax Age: 70 Years
Plain Language Summary
Simplified for easier understanding
This study is using specialized analysis of CT scan images of belly fat (called radiomics) to predict how well weight-loss surgery will work for patients with obesity and type 2 diabetes. Researchers want to find out if the type and location of fat in the body can help predict surgical outcomes.
**You may be eligible if...**
- You have a BMI greater than 27.5 kg/m²
- You have type 2 diabetes
- You are scheduled to have bariatric (weight-loss) surgery
**You may NOT be eligible if...**
- You do not have an abdominal CT scan available
- You are not having sleeve gastrectomy or Roux-en-Y gastric bypass surgery
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06169033
Related Trials
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
NCT074073481 location
A Study of LY3971297 in Healthy Participants
NCT061482727 locations
Evaluation of the Care Pathway Offered by the "Chronic Disease Unit" to Obese Patients
NCT065382201 location
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
NCT072258161 location
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT0749788023 locations